medicus pharma announces results from pre specified expanded phase 2 sknjct 003 data analysis demonstrating positive dose response

TAX_DISEASE_SYNDROMEEPU_POLICY_REGULATORYTAX_DISEASE_CARCINOMAUSPEC_POLICY1

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.